Rates of illicit drug use in the United States are broadly similar across racial and ethnic groups, a finding that surprises many people given how differently drug use is policed, treated, and discussed depending on who is using. National survey data have consistently shown that white Americans use drugs at rates equal to or higher than Black Americans, yet Black Americans face arrest, incarceration, and other consequences at vastly disproportionate rates. The gap between actual use and perceived use by race shapes nearly every downstream issue, from who gets addiction treatment to who loses custody of a child, and it is wider than most public conversations acknowledge.
What the Surveys Actually Show
Large-scale surveys paint a picture that defies common stereotypes. Among college students, for example, research using national data found that Hispanic and white students were more likely to report drug use and abuse than Asian and African American students, both before and during college.
1PubMed Central. Race/ethnicity and gender differences in drug use and abuse among college students This pattern holds across multiple substances and age groups in federal surveys. The National Survey on Drug Use and Health, the country’s largest household survey on substance use, has reported for decades that past-month illicit drug use rates among Black and white adults are close, with white Americans sometimes reporting higher rates for several drug categories.
The picture gets more complicated when you break it down by specific substances and specific populations. Alcohol use disorder, for instance, varies within broadly defined racial groups. Among Hispanic Americans, Puerto Ricans report higher rates of binge drinking and alcohol dependence than Cuban Americans or South and Central Americans, with men in particular showing wide variation across national-origin subgroups.2PubMed Central. Drinking, Alcohol Use Disorder, and Treatment Access and Utilization among U.S. Racial/Ethnic Groups Lumping all Hispanic Americans into a single category, or treating “white” as a monolith, hides meaningful differences that matter for prevention and treatment.
Methamphetamine use has also shifted over time in ways that cut across racial lines. While meth has long been associated in the public imagination with rural white communities, treatment data from 2010 to 2019 show rising injection rates among Black individuals in urban areas. Compared to 2010, the odds of injecting methamphetamine in 2019 were highest among Black cases in urban settings.3PubMed. Demographic and geographic shifts in the preferred route of methamphetamine administration among treatment cases in the US, 2010-2019 Drug trends do not stay neatly inside racial categories, and the substances and methods of use keep evolving.
The Overdose Crisis and Its Shifting Demographics
The opioid crisis was initially framed almost entirely around white communities, and for good reason: prescription opioid overdoses surged first in predominantly white, often rural, areas starting in the late 1990s. But the crisis has since shifted in ways that receive less public attention. The rise of illicitly manufactured fentanyl reshaped the racial demographics of overdose deaths dramatically.
Until about 2018, crude fentanyl overdose rates were comparable for Black and white men, and were even slightly higher for white men. By 2020, the picture had reversed. Black men were dying from fentanyl overdoses at a rate of about 35 per 100,000, compared to roughly 26 per 100,000 for white men, a gap of nearly 40 percent. A similar crossover happened among women, with Black women’s fentanyl death rate exceeding that of white women by about 19 percent in 2020.4PLOS Global Public Health. Fentanyl-driven acceleration of racial, gender and geographical disparities in drug overdose deaths in the United States Fentanyl’s infiltration of the drug supply, including stimulants and counterfeit pills, meant that communities of color with historically different substance use patterns were suddenly exposed to a uniquely lethal contaminant.
American Indian and Alaska Native communities have been hit hardest of all relative to population size. From 1999 to 2022, drug overdose death rates among American Indian and Alaska Native individuals increased roughly twelvefold, compared to a fivefold increase among white individuals over the same period.5PubMed Central. Drug overdose mortality rates among non-Hispanic American Indian/Alaska Native individuals, 1999-2022 By 2022, methamphetamine was the leading driver of overdose deaths in this population, followed by fentanyl. Researchers have documented alarming and potentially linked trends between opioid overdose and suicide among American Indian and Alaska Native populations, suggesting compound crises feeding on each other.6PubMed Central. Suicide and the opioid overdose crisis among American Indian and Alaska Natives: a storm on two fronts demanding swift action
Arrest and Incarceration Disparities
If drug use rates are broadly similar across racial groups, the criminal justice response is anything but. One of the starkest illustrations comes from a study comparing Black and white drug offenders that found no statistical difference in self-reported rates of ever having sold drugs (about 79 percent of Black participants versus 70 percent of white participants). Yet Black individuals were significantly more likely to have been arrested most recently for drug sales.7PubMed Central. Comparing Black and White Drug Offenders: Implications for Racial Disparities in Criminal Justice and Reentry Policy and Programming The gap between who sells drugs and who gets arrested for selling drugs is a microcosm of the broader pattern.
Drug courts, which are supposed to divert people with substance use disorders away from prison and toward treatment, also show racial imbalances. Research across multiple jurisdictions has found that white individuals are more likely to be admitted to drug court than Black individuals. Among those denied admission, Black individuals were more often turned away due to prior drug trafficking charges or the discretion of gatekeepers who determine eligibility, while white individuals were more commonly denied for technical legal reasons or because they declined to participate.8VCU Scholars Compass. Underrepresentation of Black Participants in Drug Court: Reasons Reported for Non-Admission in Six Jurisdictions A broader analysis of specialty courts in Indiana confirmed that Black individuals are significantly underrepresented in drug courts and overrepresented in reentry courts, patterns that appear to stem more from how eligibility is structured than from individual decisions.9Race and Justice. Specialty Courts, Special for Whom?: Examining Racial Inequities in Participation
Has Legalization Helped
Cannabis legalization and decriminalization were expected to reduce racial disparities in arrests. The results so far are mixed at best. Among adults, cannabis decriminalization has been associated with a roughly 17 percent decrease in the racial gap in arrest rates between Black and white Americans, but no such narrowing was found among youth.10PubMed Central. Cannabis decriminalization and racial disparity in arrests for cannabis possession
Full legalization has produced an even more counterintuitive result in some states. In Washington State, marijuana arrest rates for Black residents dropped significantly in absolute terms after legalization. But the relative disparity actually grew: before legalization, Black adults were arrested at about 2.5 times the rate of white adults for marijuana offenses, and after the retail market opened, that ratio climbed to about five times higher.11PubMed Central. Did marijuana legalization in Washington State reduce racial disparities in adult marijuana arrests? In Colorado and Washington, analysis of jail incarceration data found that while the Black-white jail disparity appeared to decrease slightly, the change was not statistically significant.12Journal of Criminal Justice. Pipe dreams: Cannabis legalization and the persistence of racial disparities in jail incarceration The lesson: legalizing a substance may reduce the total number of arrests and punishments, but it does not automatically fix the racial unevenness in who still gets targeted.
Disparities in Treatment and Pain Management
Racial gaps in how addiction and pain are treated in the healthcare system are well documented and stubbornly persistent. A meta-analysis covering data from 2011 to 2021 found that Black patients were less likely than white patients to receive opioid pain medication, and Hispanic patients faced a similar gap.13PubMed Central. Racial Disparities in Opioid Prescribing in the United States from 2011 to 2021: A Systematic Review and Meta-Analysis This disparity has been documented for decades and has not meaningfully narrowed over time. A separate analysis of primary care prescribing from 1999 to 2019 confirmed that non-Hispanic white and Black patients were both more likely to receive opioid prescriptions than an aggregated group of Asian, Native Hawaiian/Pacific Islander, and American Indian/Alaska Native patients, and that Hispanic patients also received fewer opioid prescriptions than non-Hispanic patients, with no substantive narrowing of these gaps over the 20-year study period.14Journal of General Internal Medicine. Racial and Ethnic Disparities in the Prescribing of Pain Medication in US Primary Care Settings, 1999–2019: Where Are We Now?
Research has traced part of this gap to false beliefs among medical trainees and providers about biological differences between Black and white patients, including myths about pain tolerance. These false beliefs are associated with less accurate treatment recommendations for Black patients.15PubMed Central. Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between blacks and whites
The disparity extends beyond pain management into addiction treatment itself. Among patients who had experienced an opioid overdose, only about 27 percent of Black patients received a buprenorphine prescription compared to roughly 45 percent of white patients.16PubMed Central. Rates of buprenorphine prescribing and racial disparities among patients with opioid overdose Among reproductive-age women on Medicaid with opioid use disorder, Black enrollees were less likely to receive buprenorphine and more likely to be referred to methadone clinics. They also experienced higher rates of treatment discontinuation for both medications.17Journal of General Internal Medicine. Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder The distinction matters because buprenorphine can be prescribed in a doctor’s office, while methadone typically requires daily visits to a specialized clinic, creating a much greater burden on patients.
When researchers controlled for criminal history and socioeconomic status in national data, the treatment gap widened rather than shrank. After adjusting for these factors, both Black and Hispanic individuals were significantly less likely than white individuals to receive substance abuse treatment.18PubMed Central. Racial-Ethnic Disparities in Substance Abuse Treatment: The Role of Criminal History and Socioeconomic Status The gap is not just about access or poverty; something more structural seems to be at work.
Harm Reduction Access
Harm reduction services, such as syringe exchange programs, naloxone distribution, and overdose prevention training, have proven effective at reducing deaths and disease transmission. But access to these services is not evenly distributed. A survey of people who use drugs found that Black non-Hispanic respondents were nearly 18 percentage points less likely to use harm reduction services and about 9 points less likely to use any substance use disorder treatment compared to white non-Hispanic respondents.19Health Services Research. Estimating Racial and Ethnic Disparities in Substance Use Disorder Treatment and Harm Reduction Services
Naloxone, the overdose-reversal drug, is a good case study for this gap. People connected to syringe services programs were far more likely to have received overdose training and to carry naloxone, regardless of race. But among people not connected to these programs, Black individuals were less likely than white nonclients to possess take-home naloxone.20PubMed Central. Racial differences in overdose training, naloxone possession, and naloxone administration among clients and nonclients of a syringe services program Given that fentanyl overdose death rates are now higher among Black Americans, this gap in naloxone access is especially consequential.
Surveillance Bias in Healthcare Settings
One underappreciated factor in racial statistics on drug use is who gets tested in the first place. Hospital drug testing practices offer a revealing window into this. A meta-analysis found that Black women and their infants were about 2.6 times more likely to be subjected to drug toxicology testing than white women and their infants, and earlier research indicated disproportionate reporting to child welfare services and child removal among Black and Hispanic families after positive tests.21PubMed Central. Racial disparities in drug toxicology testing among pregnant women & infants: a meta-analysis and systematic review
One hospital system that examined its own risk-factor-based drug testing policy during labor and delivery found that among those tested, white patients actually had a higher rate of positive results (about 17 percent) compared to patients of other racial groups (about 11 percent overall). Yet Black, low-income, single, publicly insured, and uninsured patients were disproportionately targeted for testing. Fewer than a third of the tests were ordered for a medical reason, and none had documented patient consent.22PubMed Central. Evaluating Bias and Racism in a Risk-Factor-Based Drug Testing Policy in the Labor and Delivery Department When a different hospital replaced its discretionary testing policy with a standardized universal approach, the racial gap in urine drug screening essentially disappeared: before the change, about 23 percent of Black patients were screened compared to 11 percent of white patients, while after the change, testing rates were around 4 percent for both groups. Reports to child protective services showed a similar leveling out.23PubMed Central. Racial Equity in Urine Drug Screening Policies in Labor and Delivery
This kind of surveillance bias means that official data on drug use can exaggerate racial differences. If Black mothers are tested at more than twice the rate of white mothers, the resulting “positive test” data will reflect the testing pattern as much as actual drug use patterns.
How Media Framing Shapes Perception
The way drug crises are talked about publicly has differed dramatically depending on who is perceived as the primary user. Researchers analyzing mainstream media coverage of the opioid epidemic have found that because these drugs initially affected predominantly white communities, addiction was framed as a public health crisis rather than a criminal justice problem.24Journal of Technical Writing and Communication. Visualizing a Drug Abuse Epidemic: Media Coverage, Opioids, and the Racialized Construction of Public Health Frameworks This stands in stark contrast to the crack cocaine epidemic of the 1980s and 1990s, which was overwhelmingly framed in criminal terms and directed punitive policy at Black communities. The language used to describe essentially the same phenomenon, addiction, shifts depending on the racial composition of the affected group.
Discrimination as a Driver of Substance Use
Social determinants play a significant role in who develops substance use problems, and experienced discrimination is one of the strongest predictors that cut across income and education levels. A nationally representative study found that each increase in everyday discrimination predicted higher odds of both alcohol and drug use disorders, and that each additional major discrimination event further increased those odds.25PubMed Central. Perceived Discrimination and DSM-IV-Based Alcohol and Illicit Drug Use Disorders This relationship held across racial groups, but since Black and Hispanic Americans report experiencing discrimination at higher rates, the population-level impact is uneven.
Experimental research has explored the mechanism more closely. Among young adults, the link between experiencing racial exclusion and willingness to use substances was strongest for those who already used substances as a coping strategy. People who scored low on substance-use-as-coping showed no increased willingness to use after discrimination experiences, while those who scored high showed a significant increase.26PubMed Central. Coping with Racial Discrimination: The Role of Substance Use This suggests that discrimination does not universally push people toward drug use, but it does so potently for those who have already learned to manage stress through substances.
On the protective side, research among African American adolescents has found that strong family bonds promote cultural connection and academic engagement, which in turn are associated with lower substance use.27PubMed Central. Family Factors and Mediators of Substance Use Among African American Adolescents Similarly, among multiracial youth, stronger ethnic identity was linked to higher self-esteem, and higher self-esteem was protective against drug use.28PubMed Central. Pathway of Protection: Ethnic Identity, Self-Esteem, and Substance Use among Multiracial Youth These findings point toward interventions that strengthen identity and community connection rather than treating substance use as a purely individual behavioral problem.
Gaps in the Research Itself
Even the science meant to address drug problems carries racial blind spots. A systematic review of randomized clinical trials testing medications for alcohol use disorder found that about half of the published studies did not report any information about the racial or ethnic composition of their participants. Only about 6 percent conducted analyses to see whether treatment outcomes differed by race or ethnicity.29Alcoholism: Clinical and Experimental Research. A Call to Action: A Systematic Review Examining the Failure to Include Females and Members of Minoritized Racial/Ethnic Groups in Clinical Trials of Pharmacological Treatments for Alcohol Use Disorder A parallel analysis of opioid use disorder clinical trials found that American Indian and Alaska Native individuals, who face the highest opioid-related death rates in the country, were underrepresented in the research meant to develop better treatments.30Journal of Substance Use and Addiction Treatment. Racial/ethnic representation in opioid use disorder-related clinical trials
This matters for a practical reason beyond fairness. Genetic variation in drug-metabolizing enzymes differs across populations.31PubMed. Genetic basis of drug metabolism Large-scale assessments of these enzymes across Caucasian, African, and East Asian populations have confirmed significant differences in how common certain genetic variants are.32The Journal of Clinical Pharmacology. Genetic Variation in Metabolizing Enzyme and Transporter Genes For instance, variation in an enzyme called CYP2B6, which is important for metabolizing certain HIV medications and other drugs, differs significantly across worldwide populations.33PubMed Central. Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment If clinical trials do not include diverse participants, the treatments that emerge from them may work differently, or less well, for the populations bearing the greatest burden of the problem.